Binary Bet: Ironwood’s Next Trial Will Decide If the Stock Breaks Out or Breaks Down
Ironwood (IRWD) is inexpensive on headline multiples and backed by strong cash generation and bullish 2026 LINZESS guidance, but the stock is binary: a successful confirmatory Phase 3 path for apraglutide would re-rate the shares while a negative outcome or regulatory delay would likely drive a steep sell-off. This trade idea lays out a defined lon…